European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3???2009 Update, Bone Marrow Transplantation, vol.96, issue.5, pp.709-727, 2011. ,
DOI : 10.1086/520980
National Marrow Donor Program (NMDP) European Blood and Marrow Transplant Group (EBMT) American Society of Blood and Marrow Transplantation (ASBMT), Canadian Blood and Marrow Transplant Group (CBMTG), Infectious Disease Society of America (IDSA), et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective, Bone Marrow Transplant, vol.44, pp.453-558, 2009. ,
Optimizing antifungal choice and administration, Current Medical Research and Opinion, vol.29, issue.sup4, pp.13-21, 2013. ,
DOI : 10.1185/03007995.2012.761135
Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002, Journal of Clinical Microbiology, vol.42, issue.7, pp.3142-3148, 2001. ,
DOI : 10.1128/JCM.42.7.3142-3146.2004
Candida glabrata erg1 Mutant with Increased Sensitivity to Azoles and to Low Oxygen Tension, Antimicrobial Agents and Chemotherapy, vol.48, issue.7, pp.2483-2492, 2004. ,
DOI : 10.1128/AAC.48.7.2483-2489.2004
Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials, British Journal of Cancer, vol.138, issue.10, pp.1626-1663, 2012. ,
DOI : 10.1038/sj.bmt.1702233
Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits, Antimicrobial Agents and Chemotherapy, vol.46, issue.6, pp.1857-69, 2002. ,
DOI : 10.1128/AAC.46.6.1857-1869.2002
Echinocandins ??? An Advance in the Primary Treatment of Invasive Candidiasis, New England Journal of Medicine, vol.347, issue.25, pp.2070-2072, 2002. ,
DOI : 10.1056/NEJMe020142
Effect of Antifungal Drugs on Cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 Activities in Human Liver Microsomes, Biological & Pharmaceutical Bulletin, vol.28, issue.9, pp.1805-1813, 2005. ,
DOI : 10.1248/bpb.28.1805
Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus, Clinical Infectious Diseases, vol.34, issue.1, pp.7-14, 2002. ,
DOI : 10.1086/323335
Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia, Leukemia Research, vol.38, issue.4, pp.469-74, 2014. ,
DOI : 10.1016/j.leukres.2014.01.007
Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study, European Journal of Haematology, vol.55, issue.3, p.261, 2014. ,
DOI : 10.1111/ejh.12426
A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study), Journal of Antimicrobial Chemotherapy, vol.66, issue.9, pp.2140-2145, 2011. ,
DOI : 10.1093/jac/dkr271
Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies, Antimicrobial Agents and Chemotherapy, vol.50, issue.1, pp.143-150, 2006. ,
DOI : 10.1128/AAC.50.1.143-147.2006
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia, New England Journal of Medicine, vol.356, issue.4, pp.348-59, 2007. ,
DOI : 10.1056/NEJMoa061094
Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia, M??decine et Maladies Infectieuses, vol.44, issue.4, pp.174-183, 2014. ,
DOI : 10.1016/j.medmal.2014.02.005